Syntekabio
syntekabio.com
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Syntekabio is a Daejeon company founded in 2009 that combines genomics with artificial intelligence for drug discovery. Its DeepMatcher platform screens large compound libraries against target proteins using its own supercomputing centre. The company offers discovery services to pharmaceutical partners alongside internal programmes.
News
MetaVia, Syntekabio Partner to Expand Indications for Oral MASH Drug Using AI Drug Discovery PharmExec
The AI-driven collaboration will use Syntekabio's DeepMatcher platform to identify new therapeutic targets for MetaVia's DA-1241 following promising Phase IIa trial (NCT06054815) results in patients with presumed metabolic dysfunction-associated steatohep
Read more
Report
Syntekabio shares plunge after shareholders approve 32.3 billion-won capital increase
Syntekabio shares plunge after shareholders approve 32.3 billion-won capital increase Syntekabio shares are weakening on news that the company will r
Read more
Report
Pro access
Upgrade to see all 10 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.